Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study-Reference-Cited by-同舟云学术

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Published:2018-06 Issue:10136 Volume:391 Page:2213-2224
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Deodhar Atul,Gottlieb Alice B,Boehncke Wolf-Henning,Dong Bin,Wang Yuhua,Zhuang Yanli,Barchuk William,Xu Xie L,Hsia Elizabeth C,AELION Jacob,AMARELO-RAMOS Juan,BALSA Alejandro,BERGHEA Florian,BRZEZICKI Jan,BURNETTE Michael,FRETZIN Scott,GARCÍA-CARAZO Sara,GLADSTEIN Geoffrey,GOMEZ-REINO Juan,GOODERHAM Melinda,GONZÁLEZ-FERNÁNDEZ Carlos,GOTTLIEB Alice,GRATACOS Jordi,HAALAND Derek,KAMALOVA Rima,LESZCZYNSKI Piotr,MARTIN-MOLA Emilio,MASLYANSKY Alexey,NAVARRO Federico,OPRIS Daniela,PAPP Kim,PERLAMUTROV Yuriy,PHILIPP Sandra,RACEWICZ Artur,REBROV Andrey,RELL-BAKALARSKA Maria,ROSMARIN David,RUBBERT-ROTH Andrea,SHERGY William,SHIRINSKY Ivan,SONIN Dmitry,STANISLAV Marina,SUKHAREV Alexey,TEMNIKOV Vadim,VINOGRADOVA Irina,WAYTZ Paul,YAKUSHEVICH Vladimir

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. The changing face of clinical trials in psoriatic arthritis;Ogdie;Curr Rheumatol Rep,2017

2. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells;Sherlock;Nat Med,2012

3. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability;Lee;Immunity,2015

4. Anti-IL-23 and anti-IL-17 biologic agents for the treatment of immune-mediated inflammatory conditions;Frieder;Clin Pharmacol Ther,2018

5. Expanding diversity in molecular structures and functions of the IL-6/IL-12 heterodimeric cytokine family;Hasegawa;Front Immunol,2016

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target;Expert Opinion on Biological Therapy;2024-09-08

2. Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection;Cureus;2024-09-03

3. Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET ^® in Japan;Journal of Dermatological Treatment;2024-07-04

4. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study;BMC Rheumatology;2024-05-21

5. Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials;Joint Bone Spine;2024-05